Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F12%3A12290" target="_blank" >RIV/00216208:11110/12:12290 - isvavai.cz</a>

Alternative codes found

RIV/00216224:14110/12:00062519 RIV/61989592:15110/12:33140628 RIV/00209805:_____/12:#0000361 RIV/00064190:_____/12:#0000292

Result on the web

<a href="http://dx.doi.org/10.1007/s12032-012-0293-x" target="_blank" >http://dx.doi.org/10.1007/s12032-012-0293-x</a>

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma

Original language description

Patients with metastatic renal cell carcinoma (mRCC) are often treated sequentially with targeted agents, although the optimal strategy is not known. A retrospective, registry-based study has been carried out to assess correlation between clinical response and progression-free survival in patients with mRCC treated sequentially with tyrosine-kinase inhibitors (TKIs) sunitinib and sorafenib. Data on 218 mRCC patients treated with sunitinib and sorafenib who completed therapy with both TKIs were obtainedfrom a database of mRCC patients. Standard nonparametric methods were used to assess correlation between response, PFS and length of treatment on the two agents. A strong correlation between responses to first- versus second TKI was observed (p < 0.001).No significant association was noted between the duration of therapy with the two TKIs (p = 0.056), although there was a weak statistically significant correlation between progression-free survival times in the subgroup patients who disc

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

—

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2012

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Medical oncology

ISSN

1357-0560

e-ISSN

—

Volume of the periodical

29

Issue of the periodical within the volume

5

Country of publishing house

US - UNITED STATES

Number of pages

4

Pages from-to

3321-3324

UT code for WoS article

000311513800046

EID of the result in the Scopus database

—